75 CHF CHF 75.00
AG-CR1-3599-M0055 mgCHF 75.00
AG-CR1-3599-M02525 mgCHF 235.00
|Purity Chemicals||≥99% (HPLC)|
|Solubility||Soluble in DMSO, methanol or dichloromethane.|
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||-20°C|
|Handling Advice||Keep cool and dry.|
|Use/Stability||Stable for at least 2 years after receipt when stored at -20°C.|
|Product Specification Sheet|
- Close structural analog of the selective cyclooxygenase-2 (COX-2) inhibitor celecoxib, that lacks COX-2 inhibitory function.
- Anti-proliferative, anti-tumorigenic and anti-angiogenic.
- Potent apoptosis inducer in many cancer cell lines.
- Down-regulates the expression of survivin, cyclins, MMPs and inhibits cyclin-dependent kinase activity.
- Modulates PDK-1, AKT, GSK3β, p70 S6K, PKA and MAPKAP-K1α.
- Reduces phosphorylation of ERK1/2 but not AKT T-308 or AKT S-473.
- Increases intracellular free calcium levels and potently triggers the endoplasmatic reticulum stress response (ESR), activating ER stress-associated proteins GRP78/BiP, CHOP/GADD153 and caspase-4.
- Dimethyl-celecoxib (DMC), a derivative of celecoxib that lacks cyclooxygenase-2-inhibitory function, potently mimics the anti-tumor effects of celecoxib on Burkitt's lymphoma in vitro and in vivo: A. Kardosh, et al.; Cancer Biol. Ther. 4, 571 (2005)
- DMC: novel celecoxib derivatives to rap cancer: P. Dent, et al.; Cancer Biol. Ther. 4, 583 (2005)
- Multitarget inhibition of drug-resistant multiple myeloma cell lines by dimethyl-celecoxib (DMC), a non-COX-2 inhibitory analog of celecoxib: A. Kardosh, et al.; Blood 106, 4330 (2005)
- Calcium-activated endoplasmic reticulum stress as a major component of tumor cell death induced by 2,5-dimethyl-celecoxib, a non-coxib analogue of celecoxib: P. Pyrko, et al.; Mol. Cancer Ther. 6, 1262 (2007)
- Aggravated endoplasmic reticulum stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analogue, 2,5-dimethyl-celecoxib: A. Kardosh, et al.; Cancer Res. 68, 843 (2008)
- Dimethylcelecoxib inhibits mPGES-1 promoter activity by influencing EGR1 and NF-κB: K. Deckmann, et al.; Biochem. Pharmacol. 80, 1365 (2010)
- Antiangiogenic activities of 2,5-dimethyl-celecoxib on the tumor vasculature: J.J. Virrey, et al.; Mol. Cancer Ther. 9, 631 (2010)